The increasing focus on female-centric ageing research marks an crucial shift in global healthcare priorities after years of gender exclusion in clinical studies-a concern that resonates deeply within India’s complex health landscape where conventional gender biases remain significant barriers to equitable medical progress.
For India, this development highlights two key opportunities: addressing menopausal health challenges facing its rapidly growing elderly female population and encouraging inclusive research practices within its expanding pharmaceutical sector aimed at bridging historical gaps. The emphasis on ovarian science aligns well with broader global efforts toward developing targeted treatments for chronic diseases linked with menopause-a pressing need given India’s high burden of cardiovascular issues among women post-middle age.
While international breakthroughs like rapamycin show promise, translating them effectively across diverse socio-economic strata will be critical if India intends to leverage these advancements meaningfully amidst disparities in healthcare access between rural and urban populations.
Read More: Why female health research could be the future of anti-ageing science